Genus Full Year 2023 Earnings: EPS Beats Expectations

Genus (LON:GNS) Full Year 2023 Results

Key Financial Results

• Revenue: UK£689.7m (up 16% from FY 2022).
• Net income: UK£33.3m (down 19% from FY 2022).
• Profit margin: 4.8% (down from 6.9% in FY 2022).
• EPS: UK£0.51 (down from UK£0.63 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Genus EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 28%.

The primary driver behind last 12 months revenue was the Genus PIC (Including of Genus Asia) segment contributing a total revenue of UK£349.5m (51% of total revenue). Notably, cost of sales worth UK£429.1m amounted to 62% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to UK£99.3m (44% of total expenses). Explore how GNS's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom.

Performance of the British Biotechs industry.

The company's shares are up 1.6% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Genus that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.